Patients who have had a CV event are at increased risk for a recurrence3-6
Currently there are no FDA-approved pharmacotherapies to decrease Lp(a). Optimized management of other modifiable cardiovascular risk factors in patients with elevated Lp(a) (defined as ≥50 mg/dL or ≥125 nmol/L) is imperative to reduce overall CV risk.1,2,7
If your patients have elevated Lp(a), testing their family members can uncover those who may also be at risk1,8,9
Lp(a) levels are 90% genetically determined. Cascade screening of first-degree relatives of patients with elevated Lp(a) can identify additional individuals at risk for CVD.1,8,9
Lp(a) testing may help provide a deeper understanding of your patients currently considered at lower risk7,10,11
Elevated levels of Lp(a) can increase baseline risk for a cardiovascular event. Lp(a) testing has been shown to improve the accuracy of cardiovascular risk stratification.7,10
An elevated Lp(a) result can help drive conversations with your patients about management of their other CV risk factors, treatment initiation, adherence, and lifestyle behaviors12-14
Understanding the role that elevated Lp(a) may play in familial CV risk can help reinforce proactive and heart-healthy behaviors in both patients and their family members1,12-14
Stay current on the latest news about elevated Lp(a)
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; Lp(a), Lipoprotein(a).
References: 1. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. 2. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm. Endocr Pract. 2020;26(10):1196-1224. 3. Xu N, Yao Y, Xu J, et al. Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study. Thromb J. 2022;20(1):69. 4. Welsh P, Zabiby AA, Byrne H, et al. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK Biobank. Atherosclerosis. 2024;389:1-8. 5. Madsen C, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40:255-266. 6. Berman AN, Biery DW, Besser SA, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(9):873-886. 7. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. 8. Chakraborty A, Chan D, et al. Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). Am J Prev Cardiol. 2022;10:1-6. 9. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692-711. 10. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol. 2014;64(9):851-860. 11. Willeit P, Yeang C, Moriarty PM, et al. Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events. J Am Heart Assoc. 2020;9(23):e016318. 12. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. 13. Thanassoulis G. Screening for high lipoprotein(a). Circulation. 2019;139(12):1493-1496. 14. Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022;73:32-40.